425 related articles for article (PubMed ID: 26429981)
1. Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients.
Kurose K; Ohue Y; Wada H; Iida S; Ishida T; Kojima T; Doi T; Suzuki S; Isobe M; Funakoshi T; Kakimi K; Nishikawa H; Udono H; Oka M; Ueda R; Nakayama E
Clin Cancer Res; 2015 Oct; 21(19):4327-36. PubMed ID: 26429981
[TBL] [Abstract][Full Text] [Related]
2. Phase Ib study on the humanized anti-CCR4 antibody, KW-0761, in advanced solid tumors.
Saito T; Kurose K; Kojima T; Funakoshi T; Sato E; Nishikawa H; Nakajima J; Seto Y; Kakimi K; Iida S; Doki Y; Oka M; Ueda R; Wada H
Nagoya J Med Sci; 2021 Nov; 83(4):827-840. PubMed ID: 34916725
[TBL] [Abstract][Full Text] [Related]
3. Increase in activated Treg in TIL in lung cancer and in vitro depletion of Treg by ADCC using an antihuman CCR4 mAb (KM2760).
Kurose K; Ohue Y; Sato E; Yamauchi A; Eikawa S; Isobe M; Nishio Y; Uenaka A; Oka M; Nakayama E
J Thorac Oncol; 2015 Jan; 10(1):74-83. PubMed ID: 25325779
[TBL] [Abstract][Full Text] [Related]
4. Clinical Application of Anti-CCR4 Monoclonal Antibody.
Ueda R
Oncology; 2015; 89 Suppl 1():16-21. PubMed ID: 26550987
[TBL] [Abstract][Full Text] [Related]
5. Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome.
Ni X; Jorgensen JL; Goswami M; Challagundla P; Decker WK; Kim YH; Duvic MA
Clin Cancer Res; 2015 Jan; 21(2):274-85. PubMed ID: 25376389
[TBL] [Abstract][Full Text] [Related]
6. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.
Sugiyama D; Nishikawa H; Maeda Y; Nishioka M; Tanemura A; Katayama I; Ezoe S; Kanakura Y; Sato E; Fukumori Y; Karbach J; Jäger E; Sakaguchi S
Proc Natl Acad Sci U S A; 2013 Oct; 110(44):17945-50. PubMed ID: 24127572
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
Yamamoto K; Utsunomiya A; Tobinai K; Tsukasaki K; Uike N; Uozumi K; Yamaguchi K; Yamada Y; Hanada S; Tamura K; Nakamura S; Inagaki H; Ohshima K; Kiyoi H; Ishida T; Matsushima K; Akinaga S; Ogura M; Tomonaga M; Ueda R
J Clin Oncol; 2010 Mar; 28(9):1591-8. PubMed ID: 20177026
[TBL] [Abstract][Full Text] [Related]
8. Frequency of circulating Tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially Treg-depleting agents.
de Vries IJ; Castelli C; Huygens C; Jacobs JF; Stockis J; Schuler-Thurner B; Adema GJ; Punt CJ; Rivoltini L; Schuler G; Coulie PG; Lucas S
Clin Cancer Res; 2011 Feb; 17(4):841-8. PubMed ID: 21177412
[TBL] [Abstract][Full Text] [Related]
9. [Anti-CCR4 mAb and regulatory T cells].
Kurose K; Ohue Y; Oka M
Gan To Kagaku Ryoho; 2013 Sep; 40(9):1150-5. PubMed ID: 24047773
[TBL] [Abstract][Full Text] [Related]
10. Neem leaf glycoprotein inhibits CD4+CD25+Foxp3+ Tregs to restrict murine tumor growth.
Chakraborty T; Bose A; Barik S; Goswami KK; Banerjee S; Goswami S; Ghosh D; Roy S; Chakraborty K; Sarkar K; Baral R
Immunotherapy; 2011 Aug; 3(8):949-69. PubMed ID: 21843083
[TBL] [Abstract][Full Text] [Related]
11. Tumor-infiltrating lymphocytes, particularly the balance between CD8(+) T cells and CCR4(+) regulatory T cells, affect the survival of patients with oral squamous cell carcinoma.
Watanabe Y; Katou F; Ohtani H; Nakayama T; Yoshie O; Hashimoto K
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 May; 109(5):744-52. PubMed ID: 20303300
[TBL] [Abstract][Full Text] [Related]
12. A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors.
Doi T; Muro K; Ishii H; Kato T; Tsushima T; Takenoyama M; Oizumi S; Gemmoto K; Suna H; Enokitani K; Kawakami T; Nishikawa H; Yamamoto N
Clin Cancer Res; 2019 Nov; 25(22):6614-6622. PubMed ID: 31455681
[TBL] [Abstract][Full Text] [Related]
13. Foxp3(+) regulatory T cells and natural killer cells distinctly infiltrate primary tumors and draining lymph nodes in pulmonary adenocarcinoma.
Schneider T; Kimpfler S; Warth A; Schnabel PA; Dienemann H; Schadendorf D; Hoffmann H; Umansky V
J Thorac Oncol; 2011 Mar; 6(3):432-8. PubMed ID: 21258248
[TBL] [Abstract][Full Text] [Related]
14. Porcine Treg depletion with a novel diphtheria toxin-based anti-human CCR4 immunotoxin.
Wang Z; Navarro-Alvarez N; Shah JA; Zhang H; Huang Q; Zheng Q; Madsen JC; Sachs DH; Huang CA; Wang Z
Vet Immunol Immunopathol; 2016 Dec; 182():150-158. PubMed ID: 27863545
[TBL] [Abstract][Full Text] [Related]
15. Integrated analysis of phase 1a and 1b randomized controlled trials; Treg-targeted cancer immunotherapy with the humanized anti-CCR4 antibody, KW-0761, for advanced solid tumors.
Fujikawa K; Saito T; Kurose K; Kojima T; Funakoshi T; Sato E; Kakimi K; Iida S; Doki Y; Oka M; Ueda R; Wada H
PLoS One; 2023; 18(9):e0291772. PubMed ID: 37729184
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of expanded Foxp3⁺ Helios⁻ regulatory T cells in patients with non-small cell lung cancer.
Muto S; Owada Y; Inoue T; Watanabe Y; Yamaura T; Fukuhara M; Okabe N; Matsumura Y; Hasegawa T; Osugi J; Hoshino M; Higuchi M; Suzuki H; Gotoh M
Int J Oncol; 2015 Dec; 47(6):2082-90. PubMed ID: 26460798
[TBL] [Abstract][Full Text] [Related]
17. Depletion of central memory CD8
Maeda Y; Wada H; Sugiyama D; Saito T; Irie T; Itahashi K; Minoura K; Suzuki S; Kojima T; Kakimi K; Nakajima J; Funakoshi T; Iida S; Oka M; Shimamura T; Doi T; Doki Y; Nakayama E; Ueda R; Nishikawa H
Nat Commun; 2021 Dec; 12(1):7280. PubMed ID: 34907192
[TBL] [Abstract][Full Text] [Related]
18. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study.
Ishida T; Joh T; Uike N; Yamamoto K; Utsunomiya A; Yoshida S; Saburi Y; Miyamoto T; Takemoto S; Suzushima H; Tsukasaki K; Nosaka K; Fujiwara H; Ishitsuka K; Inagaki H; Ogura M; Akinaga S; Tomonaga M; Tobinai K; Ueda R
J Clin Oncol; 2012 Mar; 30(8):837-42. PubMed ID: 22312108
[TBL] [Abstract][Full Text] [Related]
19. Changes of CD4+CD25+FOXP3+ and CD8+CD28- regulatory T cells in non-small cell lung cancer patients undergoing surgery.
Chen C; Chen D; Zhang Y; Chen Z; Zhu W; Zhang B; Wang Z; Le H
Int Immunopharmacol; 2014 Feb; 18(2):255-61. PubMed ID: 24345703
[TBL] [Abstract][Full Text] [Related]
20. Anti-CCR4 monoclonal antibody mogamulizumab for the treatment of EBV-associated T- and NK-cell lymphoproliferative diseases.
Kanazawa T; Hiramatsu Y; Iwata S; Siddiquey M; Sato Y; Suzuki M; Ito Y; Goshima F; Murata T; Kimura H
Clin Cancer Res; 2014 Oct; 20(19):5075-84. PubMed ID: 25117294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]